Tenaya Therapeutics Files 2024 10-K

Ticker: TNYA · Form: 10-K · Filed: Mar 10, 2025

Sentiment: neutral

Topics: 10-K, biotech, annual-report

TL;DR

Tenaya Therapeutics filed its 2024 10-K. All systems go for biotech operations.

AI Summary

Tenaya Therapeutics, Inc. filed its 2024 10-K on March 10, 2025, reporting on its fiscal year ending December 31, 2024. The company, focused on biological products, is incorporated in Delaware and headquartered in South San Francisco, California. Key financial data and operational details for the fiscal year 2024 are presented in this filing.

Why It Matters

This filing provides investors and stakeholders with a comprehensive overview of Tenaya Therapeutics' financial performance and business operations for the fiscal year 2024, crucial for assessing the company's current standing and future prospects.

Risk Assessment

Risk Level: medium — As a biotechnology company, Tenaya Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market acceptance.

Key Numbers

Key Players & Entities

FAQ

What is Tenaya Therapeutics' primary business focus?

Tenaya Therapeutics, Inc. is primarily involved in Biological Products (No Diagnostic Substances) as indicated by its SIC code [2836].

When did Tenaya Therapeutics' fiscal year 2024 end?

Tenaya Therapeutics' fiscal year 2024 ended on December 31, 2024.

On what date was the 10-K filing submitted?

The 10-K filing was submitted on March 10, 2025.

Where is Tenaya Therapeutics, Inc. headquartered?

Tenaya Therapeutics, Inc. is headquartered at 171 Oyster Point Blvd., Suite 500, South San Francisco, CA 94080.

What is the SEC file number for Tenaya Therapeutics?

The SEC file number for Tenaya Therapeutics is 001-40656.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on March 10, 2025 regarding Tenaya Therapeutics, Inc. (TNYA).

View full filing on EDGAR

View on Read The Filing